Cytokinetics EVP exercises options, sells 3,500

CYTOKINETICS INC (CYTK) executive Fady Ibraham Malik, EVP Research & Development, reported an option exercise-and-sell transaction.

Rhea-AI Filing Summary

CYTOKINETICS INC (CYTK) executive Fady Ibraham Malik, EVP Research & Development, reported an option exercise-and-sell transaction. On 2026-08-18 he exercised 3,500 non-qualified stock options at an exercise price of $7.80 per share, acquiring 3,500 shares of common stock, and on the same date sold 3,500 common shares at $75.82 per share. Following the option exercise, he held 30,386 options of this grant directly. The transactions were affirmed as made pursuant to a Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

Exercise and Sale: 3,500 shares ($238K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Malik Fady Ibraham

Role EVP Research & Development

Sold 3,500 shs ($265K)

Approx. gross sale proceeds $265K

Approx. exercise cost $27K

Approx. pre-tax spread $238K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	3,500	$0.00	$0.00
Exercise	Common Stock	3,500	$7.80	$27K
Sale	Common Stock	3,500	$75.82	$265K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 30,386 contracts (Direct); Common Stock — 153,902 shares (Direct)

Key Figures

Options Exercised: 3,500 shares Option Exercise Price: $7.80 per share Shares Sold: 3,500 shares +3 more

6 metrics

Options Exercised 3,500 shares Non-Qualified Stock Option (Right to Buy) exercised on 2026-08-18

Option Exercise Price $7.80 per share Conversion or exercise price of non-qualified stock options

Shares Sold 3,500 shares CYTOKINETICS common stock sold on 2026-08-18

Sale Price $75.82 per share Price for CYTOKINETICS common stock sale transaction

Options Remaining 30,386 options Non-qualified stock options held directly after the exercise

Net Share Change -3,500 shares Net buy/sell shares across reported non-derivative transactions

Key Terms

Non-Qualified Stock Option (Right to Buy), derivative security, Rule 10b5-1

3 terms

Non-Qualified Stock Option (Right to Buy) financial

"security_title: Non-Qualified Stock Option (Right to Buy)"

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Rule 10b5-1 regulatory

"aff_10b5_one true indicates a Rule 10b5-1 trading plan"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CYTK EVP Fady Malik report on this Form 4?

Fady Malik reported an exercise and sale on 2026-08-18, exercising 3,500 options for CYTOKINETICS (CYTK) shares at $7.80 and selling 3,500 common shares at $75.82 the same day.

How many CYTK options did Fady Malik exercise and at what price?

He exercised 3,500 non-qualified stock options at an exercise price of $7.80 per share. These options were originally exercisable starting 2018-03-27 and are scheduled to expire on 2028-02-27.

At what price did Fady Malik sell CYTOKINETICS (CYTK) common stock?

He sold 3,500 CYTK common shares at a price of $75.82 per share on 2026-08-18. The sale followed his same-day exercise of 3,500 stock options into common stock.

How many CYTK options does Fady Malik hold after this transaction?

After exercising 3,500 options, he held 30,386 non-qualified stock options of this grant directly. This figure reflects the remaining derivative position reported for that specific option award following the transaction.

Were Fady Malik’s CYTK trades made under a Rule 10b5-1 plan?

Yes. The filing indicates the trades were made under a Rule 10b5-1 trading plan. Such pre-arranged plans allow insiders to schedule trades in advance, which can reduce the informational significance of trade timing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 04:39 PM Accepted by SEC EDGAR 08/18/2026 - 04:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2026		M		3,500	A	$7.8	157,402	D
Common Stock	08/18/2026		S		3,500	D	$75.82	153,902	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$7.8	08/18/2026		M			3,500	03/27/2018	02/27/2028	Common Stock	3,500	$0	30,386	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)